Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Bloom Science.

    Client Virtual Booth

    BLOOM SCIENCE

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Bloom Science
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Del Mar Heights Rd, San Diego, CA 92130, US
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://bloomscience.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/bloomscience/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Bloom Science Announces Positive Topline Data from a Phase 1 Clinical Trial of BL-001, a Potential First-in-Class Therapeutic Being Developed for Both D...

    Details:

    BL-001 is a first-in-class, orally delivered, live biotherapeutic product being developed by Bloom Science for the treatment of multiple neurological diseases, including Dravet syndrome and ALS.


    Lead Product(s): BL-001

    Therapeutic Area: Neurology Product Name: BL-001

    Highest Development Status: Phase IProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 17, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Bloom Science Completes Enrollment in Phase 1 Trial of BL-001, a First-in-Class Therapy Being Developed for Dravet Syndrome

    Details:

    BL-001 is a live biotherapeutic product, designed to modulate GABA and other key bioenergetic pathways to suppress hyperexcitability which is a key driver in seizures associated with dravet syndrome and other rare developmental and epileptic encephalopathies (DEEs).


    Lead Product(s): BL-001

    Therapeutic Area: Neurology Product Name: BL-001

    Highest Development Status: Phase IProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 25, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Bloom Science Raises USD $12 Million in Series A Financing

    Details:

    The investment will enable Bloom to file an Investigational New Drug (IND) application for BL-001 in refractory epilepsy and advance into Phase I clinical trials, as well as further expand development of its platform and advance its research and talent acquisition.


    Lead Product(s): BL-001

    Therapeutic Area: Neurology Product Name: BL-001

    Highest Development Status: PreclinicalProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Leaps by Bayer

    Deal Size: $12.0 million Upfront Cash: Undisclosed

    Deal Type: Series A Financing December 09, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    The ALS Association Awards Bloom Science for Novel Microbiota-based Therapies

    Details:

    Bloom is leveraging its GOLD platform in combination with strong pre-clinical data to advance a new generation of therapeutics aimed at managing gut microbiota.


    Lead Product(s): BL-001

    Therapeutic Area: Neurology Product Name: Undisclosed

    Highest Development Status: PreclinicalProduct Type: Undisclosed

    Partner/Sponsor/Collaborator: ALS Association

    Deal Size: $0.5 million Upfront Cash: Undisclosed

    Deal Type: Funding March 17, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search